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MinireviewTargeted Gene Repair
and Its Application
to Neurodegenerative Disorders
of enzymes or proteins. The specificity of TFO binding
to the target relies on the hydrogen bonds formed be-
tween the TFO (third strand) and the purine-rich strand
of the target duplex. Gene conversion or gene repair has
been shown using a “bifunctional TFO,” a DNA molecule
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TFOs can also mutate a normal gene in cases where
the aim is not to repair a genetic mutation, but rather
to create a knockout of gene function. By couplingSynthetic DNA oligonucleotides can direct the ex-
crosslinking agents to the TFO, genes can be disabledchange of single nucleotides within coding regions of
by directly modifying the DNA sequence through amammalian genes by hybridizing to their complemen-
chemical or physical reaction. Psoralen, which is acti-tary sequence in the chromosome and creating a re-
vated by ultraviolet light and forms monoadducts andcombination joint structure with a single mismatched
interstrand crosslinks in DNA, is often used as the chem-base pair. Inherent DNA repair processes recognize
ical moiety. Chan et al. (1999) used psoralen-conjugatedthe mismatch and resolve it using the DNA sequence
TFOs to target SV40 cells carrying an episomal targetof the oligonucleotide vector as the template. This
with two mutant copies of supF reporter gene. The con-gene surgery approach can be used to repair muta-
jugated TFOs entered cells readily and bound to DNAtions or to disrupt tri-nucleotide repeats in dysfunc-
target sites in the plasmid. The TFO-psoralen conjugate-tional genes responsible for neurological disorders.
induced DNA damage disabled gene function, but as a
secondary reaction, also stimulated intramolecular re-Neuronal degeneration is a common feature of numer-
combination, causing random DNA rearrangementsous neurological disorders and aging. Clinical goals un-
within the DNA template. This secondary reaction wasderlying the study of neurodegenerative disease include
confirmed recently by Luo et al. (2000) using a mouserelief of symptoms, slowing of disease progression, and
LTK() cell line carrying two mutant forms of the herpescorrection of genetic abnormalities. Increased under-
simplex virus thymidine kinase (TK) gene in a singlestanding of the molecular basis of neurodegeneration
chromosomal locus. Intramolecular recombination wasand advances in gene transfer technologies have
demonstrated to occur at a frequency of 1%; a value thatbrought the possibility of ameliorating disease states by
is 2500-fold above background. These results illustrategenetic means closer to reality. Gene therapy can poten-
how critical it is to look for unexpected secondary reac-tially protect against neurodegenerative disease by deliv-
tions. While specific genetic modification for geneering growth factors and antioxidant or antiapoptotic mol-
knockout or gene repair is the objective, it would beecules, downregulating expression of dominant gene
disastrous to induce unintentional, random genome re-products, or compensating for loss-of-function mutations
arrangement by TFO-mediated approaches.
by protein replacement. These approaches hold great
Chimeric RNA/DNA Oligonucleotides. Recently, an
promise and have been the subject of recent excellent
experimental strategy that does not have any known
reviews (see Costantini et al., 2000, and references sequence limitation was developed for site-specific cor-
therein). Another exciting approach for hereditary dis- rection of single nucleotides using double-stranded syn-
eases with characterized mutations, however, is tar- thetic vectors. These vectors, known as chimeric RNA/
geted gene repair, a technique that involves the use of DNA oligonucleotides, are self-complementary duplex
a synthetic vector that directly induces alteration of the structures that fold spontaneously into a double hairpin
DNA sequence within the disease-related gene. This configuration (see Figure 1A). The hairpin consists of
novel therapeutic strategy is the subject of this review. a double-stranded stem connected by hairpin-capped
Targeted Gene Alteration ends, thus avoiding destabilization or destruction by
Triplex-Forming Oligonucleotides. The strategy of nu- helicases or exonucleases. The upper strand of the
cleotide alteration, where a defective gene is corrected stem, a chimeric backbone, consists of 2-o-methyl RNA
using an oligonucleotide vector mismatched to a spe- residues. The lower strand contains the targeting region
cific base, is a novel application of gene therapy. Several that is homologous to the gene sequence, with the ex-
vectors have already been developed, including triple- ception of a single base embedded in the center
helix forming oligonucleotides (TFOs), which bind as (Gamper et al., 2000a). Once bound to its complemen-
the third strand in the major groove of homopurine/ tary DNA sequence in the genome, the chimera acts as
homopyrimidine nucleotide stretches of the genome. a template for nucleotide exchange (Figure 1B). The
TFOs hybridize in a sequence-specific manner to direct overall reaction is governed by both DNA pairing and
mutagenesis; the binding process occurs independent DNA repairing activities taking advantage of processes
that function normally in the cell.
The chimera has been shown to repair genes at the3 Correspondence: ekmiec@udel.edu
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distinct, techniques. This criticism, however, was based
on the incorrect assumption that the entire process was
catalyzed by the homologous recombination enzyme
machinery, a protein-driven pathway that operates very
inefficiently in mammalian cells and acts to exchange
homologous DNA fragments through genomic integra-
tion. Recent data from eukaryotic model systems, how-
ever, supports the original proposal (see Rice et al.,
2001, and references therein) that homologous recombi-
nation is not the central process in gene repair and
that genomic integration of the chimera does not occur.
Furthermore, the original reports (Yoon et al., 1996; Cole-
Strauss et al., 1996) indicated that the conditions for
gene repair are likely to differ from cell line to cell line
and that the efficiency with which the vector enters the
cell is an absolutely critical parameter and must be opti-
mized in each case.
The first confirmation of the technique came from
experiments in which nucleotide exchange was at-
tempted in the alkaline phosphatase gene of cultured
human HuH-7 cells (Kren et al., 1997) and in factor IX
gene of rat hepatocytes in vivo (Kren et al., 1998). These
workers focused most of their efforts on optimizing the
uptake of the vectors into liver cells first and then suc-
ceeded in observing high levels of gene repair. Subse-
quent work in the Gunn rat model for Crigler-Najjar syn-
drome (liver cell targeting) (Kren et al., 1999) was the
first to demonstrate a clinically relevant response to
gene repair activity, due in large part to the optimized
method of vector delivery. In this case, the chimeric
oligonucleotides coupled to a liposomal transfer agent
were injected intravenously, a strategy ensuring that a
high percentage of the oligonucleotide will localize to
the liver. Using a similar delivery strategy, Bartlett et al.
(2000) demonstrated in vivo repair of the dystrophin
gene in a canine model for muscular dystrophy by deliv-
ering the molecules, with multiple muscle injections, toFigure 1. Targeted Gene Repair Directed by Chimeric RNA/DNA
the target site.Oligonucleotides
Evidence that the genetic change created by the chi-(A) The chimeric RNA/DNA oligonucleotide is depicted as a double
mera was actually translated to the protein level initiallyhairpin molecule with the “top” strand containing 2-o-methyl RNA
bases (lowercase letters) and the bottom strand containing DNA came from Yoon et al. (1996), but was then extended in
residues (uppercase letters). The double-stranded construct is con- targeted gene conversion of the tyrosinase gene in al-
tiguous except for a single unligated site, which enables topological bino mouse melanocytes and in the related mouse
intertwining with the target helix. A single mismatched base pair is
model, an excellent system providing the means forcontained within the chimera so that upon pairing with the helix
facile phenotypic readouts (Alexeev et al., 2000). Fur-only one mismatch is created (here lower strands).
thermore, Dickson and colleagues applied gene repair(B) The chimera hybridizes with a target site through complementary
strategies to a mutation in the Apo2E gene and achievedbase pairing, and a single mismatched base pair is created between
the bottom (all DNA) strand of the chimera and target sequence, correction frequencies exceeding 30% (Tagalakis et al.,
here G/T. The G/T base mismatch is repaired, G→A, in the first step 2001), while concurrently demonstrating distinct pheno-
and the A/C mismatch, now within the helix is repaired in a second typic changes. Again, the transfection efficiency was
event.
optimized for these cellular systems enabling high levels
of repair. Thus, delivery of sufficient levels of vector to
the target cells as well as the quality and percentage of
episomal (Yoon et al., 1996) and chromosomal (Cole- full-length synthetic vector in the sample are require-
Strauss et al., 1996) levels. In the latter case, the muta- ments for achieving detectable levels of gene repair.
tion responsible for sickle cell anemia, a single A→T Gene Repair with Single-Stranded DNA. During the
base mutation in the sixth codon of the S-globin coding last several years, our lab has developed a targeting
region, was corrected in a model cell line. Conversion vector that uses a simplified mode of synthesis and is
was detected by RFLP analysis, Southern blots, and capable of directing comparable levels of gene repair
DNA sequencing with a frequency greater than 1%. relative to the chimera. This was accomplished by taking
These initial reports were met with some skepticism a reductionist approach to elucidating the mechanism
because the number of cells exhibiting the targeted ge- of the repair reaction, which led to the functional defini-
netic change was several logs higher than the frequency tion of the DNA and RNA strands comprising the double-
stranded vector (Gamper et al., 2000a). Each part of thereported by previously established, but mechanistically
Minireview
497
causes an expansion of the polyglutamine tract in the
huntingtin protein (Wexler et al., 1987). The resulting
“gain of function” mediates the clinical and pathological
sequelae of HD, although the mechanism by which this
occurs is only beginning to be understood. Neuropatho-
logically, the most striking changes occur in the caudate
nucleus and putamen, where the medium spiny neurons
are particularly vulnerable. In diseases such as Parkin-
son’s or Alzheimer’s, identification of patients prior to
the onset of symptoms cannot be made with certainty,
and extensive neurodegeneration has to occur prior to
the initiation of clinical symptoms. In contrast, in Hun-
tington’s disease early detection permits the identifica-
tion of individuals destined to develop the disease and
early intervention is possible.
Altering a CAG to a CTG using a gene repair vector
would produce an interrupted codon repeat and this al-
tered sequence might translate into a protein that is less
likely to catalyze aggregate formation or persistence. Sin-
gle-stranded vectors could also be used to create a stop
codon (CAG→TAG) within the coding region of one hun-
tingtin gene. This would reduce the population of hunt-
ingtin proteins participating in aggregate formation and,
perhaps, produce a dominant-negative protein. Alterna-
tively, the expansion potential of interrupted triplet re-Figure 2. Targeted Gene Repair Using Modified Single-Stranded
peat regions is kept in check by an active mismatchOligonucleotide Vectors (MSSOVs)
repair (MMR) pathway. While the mechanism for thisSimilar to the chimera model outlined in Figure 1B, the modified
monitoring function is not fully understood, the processsingle-stranded oligonucleotide vector (MSSOV) creates a “D loop”
structure with its complement in the target site in the helix. The may act to stabilize hairpin unfolding in cis or in trans.
MSSOV is represented by the blue ribbon, with the bulbs at each end Hence, events that stimulate repair, such as those di-
representing the three phosphorothioate linkages. Complementary rected by gene repair vectors, might reduce the rate
base pairing is complete except for a single mismatch in the center of expansion in two ways; sequence alteration and/or
of the complex. A two-step repair process sequentially converts the
activation of the monitoring function of MMR.targeted base pair.
A unique use of single-stranded vectors that differs
from specific nucleotide repair or exchange centers
around the vector’s capacity to rearrange the inherent
chimeric oligonucleotide was synthesized as a separate
charges that form during HD protein folding. The use of
molecule and evaluated for gene repair activity in an in
oligonucleotides to direct nonspecific cellular events
vitro cell-free extract assay (Gamper et al., 2000b). Sin-
has already been demonstrated for these types of vec-
gle-stranded molecules containing RNA were almost tors in other systems (Gamper et al., 2000a, 2000b).
devoid of correction activity, while an all DNA construct Modified single-stranded DNA oligonucleotides could
was only one-fifth as active as the chimera. In the latter alter the charge distribution of proteins complexed in the
case, the lower rate of conversion may be attributable to inclusion body aggregate through a direct electrostatic
rapid degradation of the single-stranded DNA in certain interaction and induce a new protein-folding pattern.
cells. As a result, and supported by earlier results (Yama- While these model cell systems are quite informative,
moto et al., 1992), we created a new single-stranded the ultimate test will be to deliver these vectors to the
DNA vector containing a specific number of modified brain cell in vivo or to introduce them to neurons or
terminal linkages (Gamper et al., 2000a). Using this vec- neuronal stem cells ex vivo, returning the modified cells
tor, a reproducible enhancement of gene repair was back to the patient (Senut et al., 1998). As stated earlier,
observed in several eukaryotic cell lines, presumably a major roadblock in effective oligo-based therapy has
due to the increased resistance of these molecules centered around the delivery of sufficient amounts of
to exonuclease activity (Parekh-Olmedo et al., 2001). vector to the target tissue. In vivo administration will
Hence, an important advance toward elevating frequen- require direct injection into the brain or use of a peristal-
cies of gene repair has simply involved the development tic pump implanted in the patient that can perfuse brain
of a more elemental vector design, one that was easier cells. Ex vivo approaches might include the electropora-
to produce as a full-length molecule (Figure 2). tion or transformation of neurons or neuronal stem cells
Genetic Repair of Neurodegenerative Disorders. Neu- isolated from the patient and then reintroduced, combin-
rodegenerative disorders with characterized genetic ing the clinical strategies of gene therapy and cell
components could conceivably be treated with strate- therapy.
gies involving these types of oligonucleotides. At pres- The specific repair of mutations within the context of
ent, the most appropriate target may be Huntington’s the chromosome would provide a novel way to treat
disease (HD). Huntington’s disease is an autosomal hereditary diseases, especially for neurodegenerative
dominant, fully penetrant, neurodegenerative disease disorders. One advantage of using synthetic oligonucle-
otide vectors is that they are small molecules that couldresulting from a single mutation in the gene, which
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be designed to penetrate blood-brain barriers more eas-
ily than their viral counterparts. Many viral-based agents
induce an immune response and carry a limited thera-
peutic cDNA payload. The expression of these “cDNA
viral vectors” is ultimately destined to be turned off by
various processes, including methylation. Thus, subse-
quent and recurrent administration, which increases the
probability of an immune response, will be required. One
advantage of the gene repair process is that any auxiliary
gene coinjected to increase the activity of the synthetic
vector would only be required transiently; hence, reduc-
ing the probability of immune responses due to a re-
peated dosage schedule. By far, however, the most
daunting problem surrounding gene repair for neurode-
generative diseases will be managing expectations in
the field of gene therapy that has been plagued by dimin-
ishing returns.
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